CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 110 enrolled
Drug / intervention
Etanerceptdrug
Likely dose
Etanercept subcutaneous injection administered according to product monographAI-extracted
Key inclusion· 6
  • ✓Presence of psoriasis or previous evidence of psoriasis documented by dermatologist
  • ✓At least one form of psoriatic arthritis: DIP involvement, polyarticular arthritis, arthritis mutilans, asymmetric peripheral arthritis, or spinal involvement
  • ✓Active psoriatic arthritis at time of enrollment
  • ✓Greater than 3 swollen joints and greater than 3 tender/painful joints
Key exclusion· 10
  • ✕Active infections at time of initiating therapy
  • ✕Skin conditions other than psoriasis that would interfere with study evaluations
  • ✕Malignancy within past 5 years, except basal cell carcinoma or in situ cervical carcinoma
  • ✕Known hypersensitivity to etanercept or any components

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00127842
NCT00127842Phase 4Completed
CompareCT.gov

Rating Evaluations in Psoriatic Arthritis (PsA) With Enbrel®

Amgen·interventional·Posted Aug 9, 2005·Updated Apr 24, 2014

In Brief

A Phase 4 clinical trial evaluating Etanercept for Psoriatic Arthritis. Completed, enrolled 110 participants.

Detailed Summary

The overall objective of the study was to describe the long-term effectiveness and safety of etanercept in patients with psoriatic arthritis in a Canadian clinical practice setting.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPsoriatic Arthritis
Countries--
CollaboratorsWyeth is now a wholly owned subsidiary of Pfizer

Timeline

Phase 4CompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedAug 9, 2005
Enrollment StartAug 1, 2005
Primary CompletionAug 1, 2005
Study CompletionSep 1, 2009
TodayJul 2, 2026
Enrollment to primary: 0 daysPosted 20.9 years ago

Interventions

Etanerceptdrug

Administered according to the product monograph by subcutaneous (SC) injection